Pfiz­er brings Ibrance to new sub­set of breast can­cer pa­tients, re­gard­less of menopausal sta­tus

Pfiz­er has ex­pand­ed Ibrance’s use to in­clude a new sub­set of breast can­cer pa­tients, the com­pa­ny slipped in­to its quar­ter­ly earn­ings re­port on Tues­day.

The drug was ap­proved in com­bi­na­tion with an aro­matase in­hibitor (AI) in mid-De­cem­ber to treat women with HR-pos­i­tive, HER2-neg­a­tive metasta­t­ic breast can­cer re­gard­less of menopausal sta­tus, Pfiz­er an­nounced.

Ibrance was first ap­proved in post­menopausal women with ad­vanced breast can­cer back in 2015. The CDK4/6 in­hibitor has since racked up a slate of la­bel ex­pan­sions, but un­til the lat­est add-on, the AI com­bo treat­ment was on­ly in­di­cat­ed for post­menopausal women or men.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER